Quoin Pharmaceuticals, Ltd. — Director's Dealing 2024

Dec 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2024-12-09

Reporting Person: Dunn Gordon (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-09	Share Option (Right to Buy)	$0.78	A	338994	Acquired	2034-12-09	ADS (338994)	Direct

Footnotes

F1: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F2: The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028.